Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 350 participants.
Also called NCT05763875
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 350 participants
- Sponsor
- Registry
-
NCT05763875
-
- Other papers using this trial's data
- Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients Without ASCVD: The VICTORION-Mono Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Colombia, Germany, Hungary, Mexico
- Registry status
- Completed
Technical summary
Registry record NCT05763875. Randomized; triple masking; primary purpose treatment. Start 2023-03-15 (actual); primary completion 2024-06-20 (actual). Results posted on 2025-08-13.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.
- Acronym
- V-Mono
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Inclisiran
- Intervention (Drug)
- Ezetimibe
- Intervention (Drug)
- Matching Placebo for Inclisiran
- Intervention (Drug)
- Matching Placebo for Ezetimibe
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct05763875- Content hash
2a97abfadc2530a4bb2eae7e61eed962dafe3ce0e434ebe42d4abb0c5c162744